Open AccessHealth-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma
Author(s) -
Mrinal M. Gounder,
Albiruni R. Abdul Razak,
Adrienne M. Gilligan,
Hoyee Leong,
Xiwen Ma,
Neeta Somaiah,
Sant P. Chawla,
Javier Martín-Broto,
Giovanni Grignani,
Scott M. Schuetze,
Bruno Vincenzi,
Andrew J. Wagner,
Bartosz Chmielowski,
Robin L. Jones,
Jatin J. Shah,
Sharon Shacham,
Michael Kauffman,
Richard F. Riedel,
Steven Attia
Publication year - 2021
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2021-0284
Subject(s) - medicine , quality of life (healthcare) , liposarcoma , intensive care medicine , medline , pathology , nursing , sarcoma , political science , law
Objective: Compare health-related quality of life (HRQoL) of selinexor versus placebo in patients with dedifferentiated liposarcoma. Materials & methods: HRQoL was assessed at baseline and day 1 of each cycle using the European Organization for Research and Treatment of Cancer 30-item core quality of life questionnaire. Results were reported from baseline to day 169 (where exposure to treatment was maximized while maintaining adequate sample size). Results: Pain scores worsened for placebo versus selinexor across all postbaseline visits, although differences in HRQoL at some visits were not significant. Other domains did not exhibit significant differences between arms; however, scores in both arms deteriorated over time. Conclusion: Patients treated with selinexor reported lower rates and slower worsening of pain compared with patients who received placebo.